Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Glaucoma
Interventions: Pilocarpine, Prednisolone, Ofloxacin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 30 Years to 100 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Acute Otitis Externa, Swimmer's Ear
Interventions: 12 mg ciprofloxacin, Sham Control; Drug
Lead sponsor: Otonomy, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Psychosis; Acute
Interventions: risperidone, aripiprazole; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Bipolar Disorder
Interventions: Aripiprazole, placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 53
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more

Conditions: Squamous Cell Carcinoma, Carcinoma of Head/Neck
Interventions: Taxotere, Cisplatin, 5-Fluorouracil, Leucovorin, G-CSF, Ciprofloxacin; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: High Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime Exposure
Interventions: Ziprasidone, aripiprazole, quetiapine, or risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 13 Years to 18 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Cardiac Effects in Normal Healthy Volunteers
Interventions: ACHN-490 Injection, Moxifloxacin, Placebo; Drug
Lead sponsor: Achaogen, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Tuberculosis
Interventions: rifapentine, rifapentine and moxifloxacin, control; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 12 Years and older
Enrollment: 2,516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: San Francisco, California • New York, New York • Fort Worth, Texas + 2 more

Conditions: Diabetes
Interventions: Intramuscular olanzapine, aripiprazole, Intramuscular aripiprazole, olanzapine; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Diego, California

Conditions: Bronchiectasis
Interventions: Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 22
States / cities: Peoria, Arizona • Fountain Valley, California • La Jolla, California + 19 more

Conditions: Bacterial Infections
Interventions: Ciprofloxacin single dose, Ciprofloxacin triple dose; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 18
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more

Conditions: Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg, Placebo, Placebo/moxifloxacin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Schizophrenia
Interventions: Aripiprazole (Abilify®) IM Depot Injection; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 119
States / cities: Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more

Conditions: Major Depressive Disorder
Interventions: Aripiprazole+ ADT, Placebo+ ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 34
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 29 more

Conditions: Prostatitis
Interventions: levofloxacin; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 39
States / cities: Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 36 more

Conditions: Trichotillomania (Hair-Pulling Disorder), Dermatillomania
Interventions: Placebo, Aripiprazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pharmacokinetics of Isavuconazole, Healthy Volunteers
Interventions: Isavuconazole, Placebo, Moxifloxacin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Glendale, California

Conditions: QTc Interval, Pharmacokinetics
Interventions: Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose; Drug
Lead sponsor: Usona Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Headache, Migraine
Interventions: Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 4
States / cities: Anaheim, California • Cypress, California • Dallas, Texas + 1 more

Conditions: Healthy
Interventions: CR845 0.5 mcg/kg IV, CR845 3 mcg/kg IV, Moxifloxacin 400 mg Oral Tablet, Placebo; Drug · Other
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Qt Interval, Variation in
Interventions: WCK 2349, Placebo, Moxifloxacin; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Diabetes
Interventions: Olanzapine, Aripiprazole; Drug
Lead sponsor: Veterans Medical Research Foundation; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections, Tuberculosis
Interventions: Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 12
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 7 more

Conditions: Diabetic Foot Ulcers
Interventions: ofloxacin, MSI-78; Drug
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1996
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Pilocarpine Use After Kahook Goniotomy

Phase 3 Study of OTO-201 in Acute Otitis Externa

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Aripiprazole in Children and Adolescents With Bipolar I Disorder

Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis

Cardiac Safety of Indacaterol

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

A Study of Aripiprazole in Patients With Major Depressive Disorder

An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis

Aripiprazole in Body Focused Repetitive Behaviors

Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

The Treatment of Tuberculosis in HIV-Infected Patients

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers